BC Innovations | Dec 11, 2018
Distillery Therapeutics


INDICATION: Breast cancer Mouse studies suggest a vaccine based on a tetanus toxoid-MUC1 conjugate could help treat MUC1-expressing breast cancer. The conjugate consists of a 22-mer human MUC1 peptide conjugated to tetanus toxoid carrier protein,...
BC Week In Review | Mar 14, 2011
Company News

Antisoma, Biothera deal

Biothera acquired exclusive, worldwide rights to Antisoma's AS1402 for an undisclosed sum. Biothera plans to evaluate AS1402 in combination with its Imprime PGG , a soluble beta glucan derived from the cell walls of Saccharomyces cerevisiae,...
BC Week In Review | Mar 14, 2011
Company News

Antisoma cancer news

Antisoma reduced headcount to about 10 as part of its previously announced restructuring to save cash. The cuts include CMO Gray Acton. The company plans to further reduce headcount next month. In January, Antisoma announced...
BioCentury | Oct 5, 2009

3Q Approvals/3Q Setbacks

3Q Approvals/3Q Setbacks Company Approval Allos Therapeutics Inc. (NASDAQ:ALTH) FDA grants accelerated approval of Folotyn pralatrexate to treat relapsed or refractory peripheral T cell lymphoma (PTCL) Anika Therapeutics Inc. (NASDAQ:ANIK) Canada approves Monovisc to treat...
BC Week In Review | Aug 10, 2009
Clinical News

AS1402: Phase II discontinued

Antisoma discontinued development of AS1402 based on results from a Phase II trial that the company "would be very unlikely to give sufficiently positive efficacy findings." The open-label, international Phase II trial was evaluating Femara...
BioCentury | Aug 10, 2009

Ebb & Flow

With six new deals last week, the summer's hot follow-on market now has raised $1.1 billion in 13 offerings during 3Q, with more than half the quarter still ahead. The 3Q09 deal flow comes on...
BC Extra | Aug 7, 2009
Clinical News

Antisoma dropping AS1402

Antisoma plc (LSE:ASM) discontinued development of AS1402 based on results from a Phase II trial to treat locally advanced or metastatic breast cancer. The company said the study of the humanized mAb against mucin 1...
BC Week In Review | Oct 6, 2008
Clinical News

AS1402: Phase II started

Antisoma began an open-label, international Phase II trial to evaluate letrozole with or without intravenous AS1402 as first-line therapy in 110 post-menopausal women. Antisoma PLC (LSE:ASM), London, U.K.   Product: AS1402 (formerly R1550 )   Business:...
BioCentury | Apr 23, 2007

Basel ping-pong

Antisoma plc has found a new home for cancer compound AS1404 , which Roche passed on last year, as Novartis AG picked up a license in exchange for a hefty upfront fee. Antisoma said the main...
BioCentury | Jan 8, 2007

Value vs. opportunity

Some things change, some stay the same. What hasn't changed going into 2007 is that fundamentals still rule; what has changed is the absence of big cap names in this year's regulatory queue. And while...
Items per page:
1 - 10 of 32